① Datang New Energy's photovoltaic power generation increased by more than 60% during the year. What is the overall performance? ② Peer Hunting and Recruiting's losses in the first quarter narrowed by about 70% year over year. What are the highlights of revenue growth?
Major announcements for Hong Kong stocks:
1) Company news
$DATANG RENEW (01798.HK)$: A total of 11.955 million megawatt-hours of power generation was completed in the first 4 months, a decrease of 1.49% over the previous year. Among them, completed wind power decreased by 5.60% year on year, and photovoltaics increased by 62.29% year on year.
$EVERG VEHICLE (00708.HK)$: It is planned to be sold some of the shares by a series of potential sellers such as Evergrande Health International Industrial Group, and trading will resume today.
$SDHS NEW ENERGY (01250.HK)$: The cumulative total power generation in the first 4 months was about 2.112 million megawatt-hours, an increase of about 12% over the previous year.
$TONGDAO LIEPIN (06100.HK)$: Revenue for the first quarter was 471 million yuan, corporate revenue decreased by 11.2% year on year, and net loss was 13.2 million yuan, narrowing by 72.7% year on year.
During the period, the number of enterprise users was about 1,327 million, up 12.9% year on year; revenue from talent development service business reached 69.2 million yuan, up 35.7% year on year; the number of individual users increased to 97.8 million, with a year-on-year growth rate of 7.6%.
$R&F PROPERTIES (02777.HK)$: In order to make subsequent debt repayment arrangements, ensure fair disclosure of information, and protect the interests of bond investors, trading of H16 R&F 4, H16 R&F 5, H16 R&F 6, H16 R&F 8, H16 R&F 1 and H16 R&F 2 corporate bonds will be suspended from the opening of the market on May 27, 2024.
$YZYBIO-B (02496.HK)$: Data from the M701 malignant ascites phase II study were presented at the 2024 ASCO conference.
$AKESO (09926.HK)$: Idafang (evosi injection, PD-1/VEGF) was approved for marketing by the State Drug Administration.
$KINTOR PHARMA-B (09939.HK)$: The clinical trial of KX-826 tincture 1.0% to treat androgenic alopecia in adult Chinese men was approved by NMPA. This drug is one of the company's core product lines.
$HENLIUS (02696.HK)$: The marketing license application (MaaS) for the disumab biosimilar drug HLX14 was accepted by the European Medicines Agency (EMA).
$RS MACALLINE (01528.HK)$: Alibaba Software plans to transfer no more than 42.5273 million shares of the company to Hangzhou Haoyue. This transfer plan is an equity transfer between Alibaba Software and its co-actors, and has not led to a change in the total number of shares held by Alibaba Software and its co-actors.
2) Repurchase news
$TENCENT (00700.HK)$: A repurchase of 2.66 million shares was spent at HK$1,004 billion, at a repurchase price of HK$374.8-HK$382.6.
$HSBC HOLDINGS (00005.HK)$: HK$183 million was spent to repurchase 2.654,800 shares at a repurchase price of HK$68.75-69.25.
$HANG SENG BANK (00011.HK)$: It spent approximately HK$33.0943 million to repurchase 300,000 shares at a repurchase price of HK$109.3-112.
$SWIRE PACIFIC A (00019.HK)$: An amount of HK$1,80941 million was spent to repurchase 262,000 shares at a repurchase price of HK$68.4-70.
$CHINASOFT INT'L (00354.HK)$: Spend HK$129.68,500 to repurchase 3 million shares at a repurchase price of HK$4.31-4.34.
$XIAOMI-W (01810.HK)$A total of 34.1 million award shares will be awarded to 1104 selected participants.
edit/ruby